Loading...

Citius Oncology, Inc.

CTOR•NASDAQ
Healthcare
Drug Manufacturers - General
$4.11
$0.61(17.47%)

Citius Oncology, Inc. (CTOR) Stock Overview

Explore Citius Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.0/100

Key Financials

Market Cap322M
P/E Ratio-45.37
EPS (TTM)$-0.38
ROE-0.15%

AI Price Forecasts

1 Week$0.94
1 Month$-15.67
3 Months$0.00
1 Year Target$0.55

CTOR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Citius Oncology, Inc. (CTOR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.55.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -45.37 and a market capitalization of 322M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$-0.09
↓ 66.56%
EPS Growth
$-0.09
↑ 78.87%
Operating Margin
0.00%
↓ 69.72%
ROE
-14.85%
↓ 66.56%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

CEO

Leonard L. Mazur

Headquarters

420 Lexington Avenue, New York City, NY

Founded

1970

Frequently Asked Questions

;